PIK3CD and B-cell chronic lymphocytic leukemia: Furthermore, p110δ is the specific PI3K isoform producing PIP3 in response to CSF-1 stimulation in macrophages and a selective p110δ inhibitor, idelalisib, is already used in the clinic to treat patients with neoplastic B cell disorders such as chronic lymphocytic leukemia [99].